Skip to content
Akums Drugs & Pharmaceuticals logo

Akums Drugs & Pharmaceuticals IPO

MainboardListedPharma & Healthcare
Check allotment status
Issue price
₹679
Listing price
₹725
+6.77%
Current price
₹741.05
+9.14%
Subscribed
63.44x
Issue size
₹1,856.74 Cr
Listed on
6 Aug 2024

IPO timeline

  1. Opens
    30 JulTue
  2. Closes
    1 AugThu
  3. Allotment
    2 AugFri
  4. Refunds
    5 AugMon
  5. Demat credit
    5 AugMon
  6. Listing
    6 AugTue

Issue details

Price band
₹646 – ₹679 per share
Issue size
₹1,856.74 Cr
Fresh issue
Not available
Offer for sale
Not available
Issue type
Fresh capital cum OFS
Face value
₹2 per share
Lot size
22 shares
Minimum investment
₹14,938
Listing on
BSE, NSE
Exchange code
AKUMS · 544222

This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)122₹14,938
Retail (Max)13286₹1,94,194
S-HNI (Min)14308₹2,09,132
B-HNI (Min)671,474₹10,00,846

Reservation

QIB
2,03,43,188 shares (75.00% of the Offer)
NII
40,68,637 shares (15.00% of the Offer)
Retail
27,12,424 shares (10.00% of the Offer)
Employee
2,43,902 shares (0.89% of the Offer)

Allotment status

Registrar: MUFG Intime India Private Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on MUFG Intime India
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
2 Aug 2024
Refunds initiated
5 Aug 2024
Shares credited to demat
5 Aug 2024
Listing
6 Aug 2024

Grey market premium (GMP)

Updated 06 Aug 2024, 12:00 PM IST
Current GMP
₹40
+6.00%
Estimated listing price
₹719
Issue price ₹679
Highest
₹195
30 Jul
Lowest
₹40
5 Aug

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
6 Aug 2024₹40+6.00%₹719
5 Aug 2024₹40+6.00%₹719
4 Aug 2024₹80+12.00%₹759
3 Aug 2024₹90+13.00%₹769
2 Aug 2024₹120+18.00%₹799
1 Aug 2024₹130+19.00%₹809
31 Jul 2024₹168+25.00%₹847
30 Jul 2024₹195+29.00%₹874
Kostak rate
₹0

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 10 Nov 2026, 06:44 AM IST
Overall subscription
63.44x
Fully subscribed
  • QIB90.09x
  • NII (HNI)42.1x
  • Retail20.8x
  • Employee4.14x

Financials

Amounts in Rs. Crore
P/E Ratio
13580
EPS (₹)
0.05
RoE
0.11%
RoCE
3.37%
RoNW
-0.57%
PAT Margin
0.02%
EBITDA Margin
3.73%
Debt / Equity
0.69
NAV (₹)
49.59

Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.

Period ended31 Mar 202431 Mar 202331 Mar 2022
Assets3,516.373,266.533,069.05
Total Income4,212.213,700.933,694.52
Profit After Tax0.7997.82-250.87
NET Worth709.50717.19621.98
Total Borrowing491.56536.97357.95
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Akums Drugs & Pharmaceuticals
This IPO
₹1,856.74 Cr13580-0.57%0.02%63.44x+6.77%
Indegene
Mainboard · listed 13 May 2024
₹1,841.76 Cr33.5318.23%12.62%70.3x+44.91%
Symbiotec Pharmalab
Mainboard · listed 1 Sep 2026
₹1,757 Cr56.819.48%12.60%71.26x0.00%
Sagility India
Mainboard · listed 12 Nov 2024
₹2,106.4 Cr61.520.29%11.83%3.2x+3.53%
Entero Healthcare Solutions
Mainboard · listed 16 Feb 2024
₹1,600 Cr129.75-1.86%4.69%1.56x-2.33%
Paras Healthcare
Mainboard · listed 28 Oct 2026
₹1,450 Cr37.7211.83%10.38%2.23x+3.90%
Inventurus Knowledge Solutions
Mainboard · listed 19 Dec 2024
₹2,497.92 Cr54.6632%20.38%52.68x+42.96%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

IPO objectives

₹637.37 Cr total

How Akums Drugs & Pharmaceuticals plans to use the money raised, as stated in the offer document.

  1. Repayment/prepayment of all or certain borrowings of our Company₹159.91 Cr
  2. Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited₹227.09 Cr
  3. Funding incremental working capital requirements of our Company₹55 Cr
  4. Pursuing inorganic growth initiatives through acquisitions₹27.87 Cr
  5. General corporate purposes₹167.5 Cr

About Akums Drugs & Pharmaceuticals

Akums Drugs and Pharmaceuticals Limited was incorporated on 19 April 2004. It is a pharmaceutical contract development and manufacturing organisation (CDMO) offering products and services in India and overseas. It also sells branded pharmaceutical formulations and makes active pharmaceutical ingredients. Its other services include formulation R&D, preparing and filing regulatory dossiers, and testing. Some of its units are accredited by global agencies such as European GMP, WHO GMP and the US National Sanitation Foundation. Its promoters are Sanjeev Jain, Sandeep Jain and Akums Master Trust. The IPO was Rs 1,856.74 crore, with Rs 680.99 crore of fresh issue and Rs 1,175.75 crore of offer for sale, mostly by investors, with the two individual promoters also selling. Rs 387.00 crore was planned for repaying borrowings of the company and its subsidiaries.

Strengths

  • Total income rose from Rs 3,694.52 crore in FY2022 to Rs 4,212.21 crore in FY2024.
  • Rs 680.99 crore of the issue was fresh capital, with Rs 387.00 crore for repaying debt.
  • Some units carry European GMP and WHO GMP accreditation, and total income was Rs 3,700.93 crore in FY2023.
  • Total borrowing fell from Rs 536.97 crore on 31 March 2023 to Rs 491.56 crore on 31 March 2024.
  • Net worth was Rs 709.50 crore on 31 March 2024.

Risks

  • Profit was almost nil, at Rs 0.79 crore in FY2024, and the source puts the PAT margin at 0.02%.
  • The company made a loss of Rs 250.87 crore in FY2022.
  • The pre-issue P/E was 13580 at the upper band of Rs 679, based on EPS of Rs 0.05.
  • Rs 1,175.75 crore of the issue was offer for sale, and CDMO income depends on client orders.
  • Promoters and the promoter group held 82.48% before the issue and 75.29% after it.

Promoters and shareholding

Sanjeev Jain, Sandeep Jain and Akums Master Trust

Promoter holding, pre-issue
82.48%
Promoter holding, post-issue
75.29%

Anchor investors

50 investors · ₹828.8 Cr raised
InvestorShares allottedAmount% of anchor book
SBI HEALTHCARE OPPORTUNITIES FUND9,57,286₹65 Cr7.84%
SBI CONSERVATIVE HYBRID FUND5,89,094₹40 Cr4.83%
INTERNATIONAL GROWTH AND INCOME FUND7,73,212₹52.5 Cr6.33%
SMALLCAP WORLD FUND, INC7,73,168₹52.5 Cr6.33%
BLACKROCK EMERGING FRONTIERS MASTER FUND LIMITED3,68,302₹25.01 Cr3.02%
BLACKROCK GLOBAL FUNDS - INDIA FUND3,68,060₹24.99 Cr3.02%
ABU DHABI INVESTMENT AUTHORITY - MONSOON7,36,362₹50 Cr6.03%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE PURE VALUE FUND2,20,902₹15 Cr1.81%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE SMALL CAP FUND2,20,902₹15 Cr1.81%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND1,32,550₹9 Cr1.09%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE RETIREMENT FUND THE 30S PLAN88,374₹6 Cr0.72%
HSBC GLOBAL INVESTMENT FUNDS - INDIAN EQUITY3,06,834₹20.83 Cr2.51%
HSBC GLOBAL INVESTMENT FUNDS - ASIA EX JAPAN EQUITY SMALLER COMPANIES1,34,992₹9.17 Cr1.11%
FRANKLIN INDIA SMALLER COMPANIES FUND2,40,988₹16.36 Cr1.97%
FRANKLIN INDIA OPPORTUNITES FUND96,404₹6.55 Cr0.79%
TEMPLETON INDIA VALUE FUND72,314₹4.91 Cr0.59%
FRANKLIN INDIA EQUITY HYBRID FUND16,060₹1.09 Cr0.13%
FRANKLIN INDIA BALANCED ADVANTAGE FUND16,060₹1.09 Cr0.13%
DSP INDIA FUND- INDIA LONG / SHORT STRATEGY FUND WITH CASH MANAGEMENT OPTION4,41,826₹30 Cr3.62%
PUBLIC SECTOR PENSION INVESTMENT BOARD - IIFL ASSET MANAGEMENT LIMITED4,41,826₹30 Cr3.62%
TATA BUSINESS CYCLE FUND2,20,902₹15 Cr1.81%
TATA INDIA PHARMA & HEALTHCARE FUND1,47,268₹10 Cr1.21%
SBI LIFE INSURANCE CO. LTD3,68,170₹25 Cr3.02%
ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITED3,68,170₹25 Cr3.02%
VOLRADO VENTURE PARTNERS FUND IV GAMMA3,68,170₹25 Cr3.02%
MOTILAL OSWAL LARGE CAP FUND3,68,170₹25 Cr3.02%
BANDHAN SMALL CAP FUND3,68,170₹25 Cr3.02%
HDFC LIFE INSURANCE COMPANY LIMITED3,68,170₹25 Cr3.02%
EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC- EDELWEISS RECENTLY LISTED IPO FUND73,634₹5 Cr0.6%
EDELWEISS FOCUSED FUND52,140₹3.54 Cr0.43%
EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- EDELWEISS MID CAP FUND38,588₹2.62 Cr0.32%
EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- EDELWEISS LARGE CAP FUND36,806₹2.5 Cr0.3%
EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- EDELWEISS LARGE & MID CAP FUND17,534₹1.19 Cr0.14%
EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- EDELWEISS ELSS TAX SAVER FUND2,200₹0.15 Cr0.02%
MAX LIFE INSURANCE COMPANY LIMITED1,91,444₹13 Cr1.57%
MAX LIFE INSURANCE CO. LTD. - PURE GROWTH FUND29,458₹2 Cr0.24%
DESTINATIONS INTERNATIONAL EQUITY FUND, A SERIES OF BRINKER CAPITAL DESTINATIONS TRUST2,20,902₹15 Cr1.81%
ADITYA BIRLA SUN LIFE INSURANCE COMPANY LIMITED2,20,902₹15 Cr1.81%
JUPITER INDIA FUND2,20,902₹15 Cr1.81%
FLORIDA RETIREMENT SYSTEM - ALLSPRING GLOBAL INVESTMENTS, LLC (EMSC)2,20,902₹15 Cr1.81%
CARMIGNAC PORTFOLIO2,20,902₹15 Cr1.81%
NEUBERGER BERMAN EMERGING MARKETS EQUITY FUND2,20,902₹15 Cr1.81%
ALLIANZ GLOBAL INVESTORS FUND - ALLIANZ INDIA EQUITY2,20,902₹15 Cr1.81%
FOUNDERS COLLECTIVE FUND1,23,706₹8.4 Cr1.01%
CITRUS GLOBAL ARBITRAGE FUND1,23,706₹8.4 Cr1.01%
PGIM INDIA TRUSTEE PRIVATE LIMITED A/C - PGIM INDIA SMALL CAP FUND1,23,706₹8.4 Cr1.01%
RELIANCE NIPPON LIFE INSURANCE CO LIMITED1,23,706₹8.4 Cr1.01%
JM FINANCIAL MUTUAL FUND - JM SMALL CAP FUND60,114₹4.08 Cr0.49%
JM FINANCIAL MUTUAL FUND - JM AGGRESSIVE HYBRID FUND15,042₹1.02 Cr0.12%
CANARA HSBC LIFE INSURANCE CO LTD75,108₹5.1 Cr0.62%

Registrar, lead managers and documents

Registrar

MUFG Intime India Private Limited

022-49186000

akumsdrugs.ipo@linkintime.co.in

Company contact

+91 11 6904 1000

cs@akums.net

Akums Drugs & Pharmaceuticals IPO: common questions

1.When does the Akums Drugs & Pharmaceuticals IPO open and close?

The Akums Drugs & Pharmaceuticals IPO opens on 30 Jul 2024 and closes on 1 Aug 2024.

2.What is the price band of the Akums Drugs & Pharmaceuticals IPO?

The price band is ₹646 – ₹679 per share, with a lot size of 22 shares and a minimum investment of ₹14,938.

3.What is the size of the Akums Drugs & Pharmaceuticals IPO?

The issue size is ₹1,856.74 Cr (Fresh capital cum OFS).

4.What is the GMP of the Akums Drugs & Pharmaceuticals IPO?

The last reported grey market premium is ₹40 per share as of 06 Aug 2024, 12:00 PM IST. GMP is unofficial and changes frequently.

5.When is the Akums Drugs & Pharmaceuticals IPO allotment?

The basis of allotment is expected on 2 Aug 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.

6.When will the Akums Drugs & Pharmaceuticals IPO list?

The shares listed on 6 Aug 2024 on BSE, NSE.

7.Who is the lead manager of the Akums Drugs & Pharmaceuticals IPO?

The book running lead managers are Axis Capital, ICICI Securities, Ambit Capital, Citigroup Global Markets India Pvt. Ltd, and the registrar is MUFG Intime India Private Limited.

8.What will the money raised in the Akums Drugs & Pharmaceuticals IPO be used for?

As stated in the offer document, the proceeds are for: Repayment/prepayment of all or certain borrowings of our Company; Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited; Funding incremental working capital requirements of our Company; Pursuing inorganic growth initiatives through acquisitions; General corporate purposes.

9.How can my company launch an IPO like Akums Drugs & Pharmaceuticals?

Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393